secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0001714899-24-000205
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali partner Sanofi discontinues K2 Phase 2 study of oditrasertib in MS after missing endpoints
--------------------------------------------------------------------------------

- Sanofi discontinued K2 Phase 2 study of oditrasertib (SAR443820/DNL788) in multiple sclerosis.
- Study did not meet primary and key secondary endpoints based on serum neurofilament light chain levels.
- Denali was informed by partner Sanofi; no further details on safety or next steps provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000205/0001714899-24-000205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000205/dnli-20241010.htm
  HTML page:      https://secwatch.observer/filing/0001714899-24-000205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer